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Here, we provide additional data addressing the individual and
combined associations of type 2 diabetes (T2DM) and of peripheral
artery disease (PAD) with future cardiovascular events in a pro-
spective cohort study including 338 PAD patients and 711 patients
who did not have PAD. Subgroup analyses regarding patient age as
well as additional Cox regression models taking into account
medications are presented. This data article is related to a research
article titled “Single and combined effects of peripheral artery
disease and of type 2 diabetes mellitus on the risk of cardiovas-
cular events: a prospective cohort study” (Saely et al., 2018).
& 2018 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).vier Inc. This is an open access article under the CC BY license
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ore speciﬁc subject area Vascular medicine, epidemiology
ype of data Figure, tables
ow data were acquired National registries, blood pressure recordings, body weight and
height measurements, standard laboratory procedures for the
measurement of biochemical variables, review of patient registries;
data were entered into Microsoft Access and evaluated using the
software package SPSS 24.0 for Windows (SPSS, Chicago, IL, USA).ata format Analyzed data
xperimental factors Prospective cohort study including 1049 subjects, 338 with per-
ipheral artery disease and 711 without peripheral artery disease.
These patients were prospectively followed, and cardiovascular
events were recorded.xperimental features Over a mean of 7.2 years cardiovascular events were prospectively
recorded in 1049 subjects, encompassing 4 groups: 558 with neither
PAD nor diabetes, 153 with T2DM but without PAD, 192 with PAD
but without T2DM and 146 with the combination of PAD and T2DM.ata source location Feldkirch, Austria and Berne, Switzerland
ata accessibility Data are included as a collated ﬁle
elated research article Christoph H. Saely, Marc Schindewolf, Daniela Zanolin, Christine F.
Heinzle, Alexander Vonbank, Guenter Silbernagel, Andreas Leiherer,
Heinz Drexel, Iris Baumgartner: Single and combined effects of
peripheral artery disease and of type 2 diabetes mellitus on the risk
of cardiovascular events: a prospective cohort study (Atherosclerois
2018; in press) [1]Value of the data
 The data presented here clarify the individual and combined associations of T2DM and of PAD with
future cardiovascular events and thus help to better understand the cardiovascular risk associated
with these entities.
 The data presented here show that age does not signiﬁcantly affect the impact of T2DM on car-
diovascular event risk in patients with or in subjects without PAD and thus help to understand the
role of age for the cardiovascular risk associated with T2DM and PAD.
 The data presented here show that major cardiovascular medications do not signiﬁcantly affect the
associations between T2DM, PAD and cardiovascular events.
 The data presented here highlight the very high cardiovascular risk of PAD patients, in particular of those
who additionally have T2DM. They should stimulate future epidemiologic research and provide a ratio-
nale to speciﬁcally include these patients in intervention trials aiming to reduce cardiovascular events.1. Data
The data presented here are related to a research article published separately by the same authors
[1]. Data are shown (i) for age subgroups (Fig. 1 and Table 1) and (ii) regarding Cox regression analyses
adjusting for major cardiovascular medications (Table 2).
Table 1
Cardiovascular risk associated with PAD and with T2DM in age-groups.
Age o65 years Age Z65 years pinteraction
PAD as a predictor of cardiovascular events in the total cohort 6.08 [3.96–9.32] 4.39 [3.00–6.44] 0.728
PAD as a predictor of cardiovascular events in T2DM patients 5.40 [2.59–11.25] 10.90 [5.22–22.74] 0.115
PAD as a predictor of cardiovascular events in patients
without T2DM
6.32 [3.60–11.09] 2.72 [1.66–4.44] 0.954
T2DM as a predictor of cardiovascular events in the total cohort 1.87 [1.26–2.77] 1.75 [1.29–2.37] 0.992
T2DM as a predictor of cardiovascular events in PAD patients 1.56 [0.93–2.63] 2.02 [1.37–2.98] 0.803
T2DM as a predictor of cardiovascular events in patients
without PAD
1.45 [0.75–1.2.81] 1.09 [0.62–1.91] 0.440
Hazard ratios (HR) are shown adjusted for age, gender, BMI, smoking, hypertension, LDL cholesterol, and HDL cholesterol.
Fig. 1. Prevalence of age Z65 years in patient categories considering both the presence of PAD and of type 2 diabetes. From our
patients, 513 were o65 years and 536 were 65 years or older. Among patients with PAD 61.2% and among subjects without
PAD 46.3% were Z65 years (p o 0.001). Considering both PAD and the presence of T2DM, the prevalence of an age Z65 years
was 45.3% in those with neither PAD nor T2DM, 49.7% in those with T2DM but without PAD, 60.9% in those with PAD but
without diabetes and 61.7% in those with PAD plus diabetes, respectively. The prevalence of an age Z65 years neither among
subjects without (p ¼ 0.341) nor among those with PAD (p ¼ 0.895) was associated with the presence of T2DM.
Table 2
Associations of PAD and of T2DM with cardiovascular events after adjustment for major cardiovascular medications.
Hazard ratio
PAD as a predictor of cardiovascular events in the total cohort 5.07 [3.72–6.91]
PAD as a predictor of cardiovascular events in T2DM patients 6.73 [4.05–11.16]
PAD as a predictor of cardiovascular events in patients without T2DM 4.11 [2.75–6.16]
T2DM as a predictor of cardiovascular events in the total cohort 1.68 [1.32–2.14]
T2DM as a predictor of cardiovascular events in PAD patients 1.87 [1.36–2.57]
T2DM as a predictor of cardiovascular events in patients without PAD 1.18 [0.77–1.80]
Hazard ratios are shown adjusted for age, gender, BMI, smoking, hypertension, LDL cholesterol, HDL cholesterol and, addi-
tionally, for the use of statins, angiotensin converting enzyme/angiotensin II receptor blocking agents, beta receptor blocking
agents and aspirin as well as clopidogrel.
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To obtain the present data, we enrolled 1049 subjects, including 338 with PAD and 711 without
PAD at the Academic Teaching Hospital Feldkirch, Austria and at the Division of Angiology at the
University Hospital Berne, Switzerland from September 2006 through January 2012.
As patients with PAD, we enrolled 338 Caucasian patients who were symptomatic for PAD and had
an ankle brachial index o0.9 or previous revascularization of peripheral arteries who underwent
C.H. Saely et al. / Data in Brief 21 (2018) 1716–1720 1719routine duplex sonography and in whom PAD was veriﬁed by sonography. Patients with type 1 dia-
betes or with Fontaine stage IV were not enrolled.
As subjects without PAD we enrolled individuals from a cohort of 711 consecutive Caucasian
patients referred for coronary angiography for clinical reasons, in whom signiﬁcant CAD with lumen
narrowing Z50% was ruled out angiographically [2] and who neither at present nor in the past had
any signs or symptoms of PAD such as intermittent limb claudication, history of PAD or peripheral
revascularization, or ABI o0.9). Patients with a history of acute coronary syndromes within three
months prior to baseline angiography and subjects with type 1 diabetes were not enrolled.
We recorded height and weight as well as waist and hip circumferences at baseline. Data on
conventional cardiovascular risk factors such as a history of smoking, hypertension, established
diabetes, and a family history of atherosclerotic disease were obtained by a standardized interview.
Systolic as well as diastolic resting blood pressures were measured by the Riva-Rocci method in a
sitting position at the day of hospital admission after a 1 h rest. To deﬁne hypertension we used the
2013 ESC/ESH guidelines [3], and we diagnosed type 2 diabetes according to 2018 ADA clinical
practice recommendations [4].
The incidence of cardiovascular events and of death was recorded during follow-up. We annually
collected time and cause of death from a national registry (Statistik Austria, Vienna, Austria) as well as
from hospital registries and telephone contacts; data on non-fatal events were biannually obtained
using standardized interviews.
As the primary endpoint, a composite consisting of coronary death (fatal myocardial infarction,
sudden cardiac death, mortality from congestive heart failure due to CAD), fatal ischemic stroke, non-
fatal myocardial infarction, non-fatal ischemic stroke, and need for revascularization coronary artery
bypass grafting (CABG), percutaneous coronary intervention (PCI), revascularization in the carotid or
peripheral arterial beds or amputation at the lower extremities was used. Coronary angioplasty,
bypass surgery, revascularizations of the peripheral arteries or amputation at the lower extremities
were regarded as end points only if not scheduled as a consequence of the ﬁndings of the baseline
examinations. We achieved a follow-up rate of 98.3%.
Our protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki, and the Ethics
Committees of the Universities of Innsbruck and Berne approved it; written informed consent was
given by all participants.
Venous blood samples were drawn after an overnight fast of at least 12 h and measurements of
biochemical variables were performed from fresh serum samples, as described previously [5,6].
Serum levels of triglycerides, total cholesterol, low density lipoprotein (LDL) cholesterol, high density
lipoprotein (HDL) and cholesterol, C-reactive protein (CRP), and plasma glucose were measured on a
Cobas Integra 800s (Roche, Basel, Switzerland) and Haemoglobin A1c (HbA1c) by high-performance
liquid chromatography on a Menarini-Arkray KDK HA 8140s (Arkray KDK, Kyoto, Japan).
We tested differences in baseline characteristics for statistical signiﬁcance with the Chi-squared
and the Mann-Whitney U-tests for categorical and continuous variables, respectively. To compare
differences in the cumulative incidence rates of cardiovascular events the Wilcoxon-Gehan statistic
was applied. We derived adjusted hazard ratios for the incidence of ﬁrst cardiovascular events from
Cox proportional hazards models; continuous variables were z-transformed for these calculations.
Data are given as mean (7standard deviation) if not denoted otherwise. All statistical analyses were
performed using the software package SPSS 24.0 for Windows (SPSS, Chicago, IL, USA).Acknowledgements
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